« Back to Record
Citation APA

Asselah, T., Scott, J. T., Van Dooren, G., Lonjon-Domanec, I., Schlag, M., Buti, M., Moreno, C., Sarrazin, C., Gschwantler, M., Foster, G. R., Craxí, A., Buggisch, P., Ryan, R., & Lenz, O. (2016). An open-label trial of 12-week simeprevir plus Peginterferon/Ribavirin (PR) in treatment-naïve patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PloS one, 11(7), e0158526. doi:10.1371/journal.pone.0158526


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/236916

Asselah, T., Scott, J. T., Van Dooren, G., Lonjon-Domanec, I., Schlag, M., Buti, M., Moreno, C., Sarrazin, C., Gschwantler, M., Foster, G. R., Craxí, A., Buggisch, P., Ryan, R., & Lenz, O. (2016). An open-label trial of 12-week simeprevir plus Peginterferon/Ribavirin (PR) in treatment-naïve patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PloS one, 11(7), e0158526. doi:10.1371/journal.pone.0158526